Media stories about Pharmacyclics (NASDAQ:PCYC) have been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pharmacyclics earned a news impact score of 0.05 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.2760176523106 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/11/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-pharmacyclics-pcyc-share-price.html.

About Pharmacyclics

Pharmacyclics, Inc is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company’s commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer.

Insider Buying and Selling by Quarter for Pharmacyclics (NASDAQ:PCYC)

Receive News & Ratings for Pharmacyclics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmacyclics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.